| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39706 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| US5763426 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| US6787529 | LEO PHARMA AS | Topical composition |
Jan, 2020
(4 years ago) | |
Taclonex is owned by Leo Pharma As.
Taclonex contains Betamethasone Dipropionate; Calcipotriene.
Taclonex has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Taclonex are:
- USRE39706
- US5763426
- US6753013
- US6787529
Taclonex was authorised for market use on 09 January, 2006.
Taclonex is available in suspension;topical dosage forms.
Taclonex can be used as psoriasis, treatment of moderate plaque psoriasis.
The generics of Taclonex are possible to be released after 27 January, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 23, 2017 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 09 January, 2006
Treatment: Psoriasis; Treatment of moderate plaque psoriasis
Dosage: SUSPENSION;TOPICAL
TACLONEX family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| US6787529 | LEO PHARMA AS | Topical composition |
Jan, 2020
(4 years ago) | |
Taclonex is owned by Leo Pharma As.
Taclonex contains Betamethasone Dipropionate; Calcipotriene Hydrate.
Taclonex has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Taclonex are:
- US6753013
- US6787529
Taclonex was authorised for market use on 29 October, 2015.
Taclonex is available in suspension;topical dosage forms.
Taclonex can be used as plaque psoriasis.
The generics of Taclonex are possible to be released after 25 January, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 25, 2022 |
| Pediatric Exclusivity(PED) | Jan 25, 2023 |
| New Indication(I-659) | Oct 17, 2015 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: Plaque psoriasis
Dosage: SUSPENSION;TOPICAL
TACLONEX family patents